AEON Biopharma Engages in Major Global Investor Conference 2024
AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company dedicated to developing a botulinum toxin complex for various therapeutic needs, has announced its participation in a significant investment conference. Marc Forth, AEON’s President and Chief Executive Officer, will provide a comprehensive corporate overview. The presentation is scheduled for September 11, 2024, at 1:30 PM ET at the H.C. Wainwright 26th Annual Global Investment Conference.
Marc Forth will also engage in one-on-one meetings with institutional investors during the conference. Interested investors are encouraged to connect with their H.C. Wainwright representatives to schedule meetings.
For those unable to attend in person, a live webcast of the event will be made available through the conference host, enabling broader access to AEON's corporate presentation.
About AEON Biopharma
AEON is at the forefront of biopharmaceutical innovation, focusing on its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection. The primary goal is to address debilitating medical conditions, particularly in the neurosciences sector. Notably, ABP-450 is identical to the botulinum toxin complex currently marketed for cosmetic applications by Evolus under the brand name Jeuveau.
The manufacturing of ABP-450 adheres to stringent Good Manufacturing Practice (cGMP) guidelines and occurs in a facility approved by the U.S. Food and Drug Administration, Health Canada, and the European Medicines Agency. Furthermore, ABP-450 has received biosimilar approval in Mexico and India. AEON holds exclusive development and distribution rights for therapeutic applications of ABP-450 across the United States, Canada, the European Union, the United Kingdom, and several other international markets.
AEON has assembled a highly skilled management team with vast experience in biopharmaceuticals and expertise in botulinum toxin development and commercialization, positioning the company well for its future endeavors.
For more information about AEON Biopharma, please visit www.aeonbiopharma.com.
Contacts
Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Frequently Asked Questions
1. What is the primary focus of AEON Biopharma?
AEON Biopharma focuses on developing its proprietary botulinum toxin complex, ABP-450, targeting debilitating medical conditions with an emphasis on neurosciences.
2. When will AEON Biopharma present at the H.C. Wainwright Conference?
AEON Biopharma will present on September 11, 2024, at 1:30 PM ET during the H.C. Wainwright 26th Annual Global Investment Conference.
3. How can investors participate in meetings with AEON?
Institutional investors interested in meetings during the conference should contact their H.C. Wainwright representatives to schedule a one-on-one meeting.
4. Is the ABP-450 product approved in any regions?
Yes, ABP-450 is approved as a biosimilar in Mexico and India, and it is manufactured under strict compliance with regulatory standards.
5. How can investors learn more about AEON Biopharma?
Investors can find more information about AEON Biopharma by visiting their official website at www.aeonbiopharma.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Global Citizen Campaign Raises $1 Billion to Combat Poverty
- Intuitive Machines' NASA Contract: A Game Changer for Investors
- Understanding Upcoming Employment Reports and Economic Trends
- Real Estate Bonds Experience Unprecedented Surge in Returns
- Understanding the Shifting Landscape of Freight Market Trends
- Examining the Future of PDD Holdings amidst Regulatory Changes
- The Rise of China's Stock Market: Opportunities Ahead
- MLOVE to Showcase Innovative Rangers Speakers at Global Event
- Kelun-Biotech Showcases Promising TROP2-ADC Research Insights
- North Korea's Warning on US Military Aid to Ukraine Raises Concerns
Recent Articles
- Covenant Logistics Group Declares Quarterly Dividend Payment
- Key Features to Look for When Choosing a Conversational AI Company
- NORBIT Increases Share Capital Through Employee Incentives
- PickleJar Partners with Thompson Square for Fan Engagement
- BLAQclouds, Inc. Launches BLAQlp.io And ZEUS Acquisition Update
- Embassy Bancorp, Inc. Reports Financial Results for Mid-2024
- TEPKINLY Secures European Approval for Follicular Lymphoma Treatment
- Strategic Development Agreement for Enhanced Production at Oza Field
- Solvay's Share Buyback Program Updates and Company Overview
- Scorpius Holdings Completes Successful Public Offering of Shares
- Shell plc Announces Share Buy-Back Transaction Details
- XPENG Unveils XOS 5.2 OTA Update, Revamping User Experience
- Artisan Partners Growth Team Announces Portfolio Management Shift
- Security Federal Corporation Expands Stock Repurchase Program
- Voltage Shifts: Impact of Brazil’s Grid Operator on Voltalia
- Volta Finance Limited's Performance and NAV Update for July 2024
- GivBux, Inc. Files SEC Form 10 for OTCQB Reporting Status
- Ethical Web AI Unveils Demonstrable Ethical Web Product
- Rexel's Share Trading Disclosure: August 12 to August 16, 2024
- Monthly Report on Voting Rights and Shares for Marie Brizard
- Global Tech Industries Group Reclaims AI Commerce Stock Assets
- Landsbankinn Completes Successful Covered Bond Auction Results
- DEME Group NV Shares Buyback Program Latest Update
- Crossject Appoints Tony Tipton as U.S. COO for ZEPIZURE Launch
- Share Purchase Update for Cargotec Corporation in August 2024
- Technip Energies Share Buyback Report: August 2024 Analysis
- ProPhase Labs Set to Participate in Virtual Investor Summit
- Emerita Resources Secures $6 Million in First Credit Tranche
- IZEA Flex Recognized as Top Influencer Marketing Platform 2024
- AYR Cannabis Expands Retail Presence with New Manchester Store
- Davidson Kempner Capital Management Updates on International Paper
- Davidson Kempner Capital Management LP's Public Disclosure Report
- Resolutions From Vilniaus Baldai AB Shareholders Meeting
- MJ Sully Elevated to Senior Managing Director at Peapack Private
- OSB Group PLC's Recent Shareholding Update and Company Overview
- Anthony Germinaro Joins PetVivo Holdings as Business Manager
- SKYX Partners with EGLO for Lighting Innovations Worldwide
- Ainos Introduces AI Nose Technology Enhancing Factory Safety
- Riksbank Certificates Buyback Overview and Details
- Middlefield Canadian Income PCC Reports Estimated NAV Details
- Peoples Bancorp Announces Regular Cash Dividend Payment
- Mullen's Class 3 EV Truck Order for Sustainability Initiatives
- AlphaVest Acquisition Corp Enters Merger Agreement with AMC Corp
- Manager's Transactions Report for Schouw & Co. Revealed
- Spirit Blockchain Capital Teams Up with SlamNet for SLAM Token
- Board Transactions Reporting and Company Overview of Svitzer
- Telos Corporation Expands TSA PreCheck Enrollment Locations
- United Health Products Update on FDA Approval Process
- Accelerating Deployment of Battery Storage Solutions Across Asia
- Pandora's Share Buyback Program: Latest Transactions and Impact